Background: Treatment data for prostate cancer can be obtained from a variety of sources. Each of these sources has its own strengths and weaknesses and is subject to error.
In general, the data on both the received treatment and the subsequent outcomes can be obtained from a variety of sources including patients' self-report, surveys of treating physicians, and medical record abstraction. The current study is focused on treatment of prostate cancer as reported from six different sources-patient and caregiver interviews, physician questionnaires, and medical record abstracts. As each of the data sources has its own strengths and weaknesses [3] [4] [5] [6] [7] [8] , it is important to evaluate the level of disagreement among different methods of data collection. In addition, a better understanding of factors that are associated with the presence and direction of reporting error may instruct optimal choice of data collection methods in future cohort studies of prostate cancer patients.
materials and methods data sources
The study design involved recruitment of a cohort (target sample size 300) of newly diagnosed localized prostate cancer patients who were £75 years of age and resided in 1 of the 33 counties comprising Southwest Georgia (SWGA), a largely rural area with the most recent census-based population of 724 327 people [9] .
The cohort recruitment was based on a rapid case ascertainment system, which relied on weekly transmission of pathology reports from the regional Georgia Comprehensive Cancer Registry (GCCR) office to the projectcoordinating center. The main data collection procedures summarized schematically in Figure 1 included three in-person patient interviews: at baseline (within 1-2.5 months after diagnosis), at 6 months after diagnosis (when the treatment was still ongoing or just complete), and at 12 months after diagnosis. In addition to a patient interview, there was an interview with the primary caregiver (usually the spouse) at 6 months and a written questionnaire sent 12 months after the diagnosis to the patient's physician (usually a urologist or a radiation oncologist) responsible for the prostate cancer treatment.
Information from medical records was collected by trained GCCR abstractors who supplemented the routine data collected for cancer registration purposes with additional treatment-and disease-related variables. The medical record abstraction was carried out at the end of the study, roughly at the time of, or soon after, the final 12-month interview. Essentially all treatment was either completed or at least initiated at the time of the 6-month interview.
data analyses
For each of the five data sources, each of the four main treatment modalities-prostatectomy, external beam radiation therapy (EBRT), brachytherapy, and hormone therapy-was coded as a dichotomous variable ('received' versus 'not received'). Information on expectant management (active surveillance) could not be ascertained in these data because nearly all the patients that reported considering active surveillance at baseline ended up receiving some treatment by the 6-month follow-up.
The level of inter-reporting agreement was evaluated by calculating a kappa statistic for each possible two-way and four-way combination of the four subjective reporting resources (two patient interviews, a caregiver interview, and a doctor's questionnaire) and for each treatment. Kappa statistic evaluates the level of agreement that exceeds that occurring by chance alone [10] . Kappa values of <0.20, 0.21-0.40, 0.41-0.60, and 0.61-0.80 were interpreted as showing poor, fair, moderate, and good agreement, respectively [11] . Accuracy of the interview-or questionnaire-based treatment information was assessed by calculating the sensitivity and specificity for each reporting source and for each of the four treatments using the end-of-study medical record abstraction as the 'gold standard' in all analyses.
Multivariate logistic regression analyses evaluated the relationship between various patient characteristics and misreporting of treatment (compared with medical records) at 6 and 12 months of follow-up. The independent variables for each model included patient's age (65+ versus £64 years), race (African-Americans versus Caucasians), marital status (married versus not married), education (at least some college versus high school or less), employment status (working at least part time versus not working), annual household income ( ‡$40 000 versus <$40 000), and the number of comorbidities (at least two versus one or none). The analyses of the accuracy of caregiver's interviews, in addition to patient-related variables listed above, also included caregiver's characteristics (age, relation to the patient, and education), and the analyses evaluating the accuracy of physicians' reports included, along with individual patient-related variables, three physician characteristics (specialty, board certification, and number of years in practice). The analyses of physician-reported treatment were carried out using generalized estimating equations (GEE) for binary data with a logit link function [12] . The GEE modeling approach allowed us to obtain multivariate-adjusted odds ratios (ORs) while accounting for clustering of observations (because of the same reporting characteristics) for each physician. The multivariate analysis results were expressed as adjusted ORs and 95% confidence intervals (CIs).
All statistical analyses were carried out using SPSS 11.5 for Windows (LEAD Technologies Inc., Chicago, IL) and (for kappa analyses) Computer Programs for Epidemiologic Analyses v.4.0 (authors: Abramson, JH and Gahlinger, PM; available at http://sagebrushpress.com).
results
As shown in Figure 1 , the initial cohort included 319 patients interviewed at baseline. The 6-month follow-up interview was conducted among 85% of cohort members and 81% of patients' caregivers. At 12 months of follow-up, data from patient interviews and physician questionnaires were available for 77% and 76% of cohort members, respectively. The medical record abstracts were available for 309 (97%) of 319 patients.
A comparison of patient characteristics across different data sources (Table 1) indicated only minor differences with respect to age (means ranged from 63.3 to 63.5), education (percentages of those with least some college education ranged from 45% to 47%), and proportion of patients with two or more comorbidities (range 52%-55%). African-Americans constituted 42% of the baseline cohort, compared with 40% of the participants in the 6-month interview and 38% of the participants in the 12-month interview. Patients with completed doctors' questionnaires included 44% of AfricanAmerican men (Table 1 ). Among 257 caregivers that provided treatment data, 231 (89.9%) self-identified as the patient's wife or partner. Caregivers in this study were somewhat younger (mean age 58.6 years) than the prostate cancer patients (mean 63.3 years).
A total of 22 physicians responded to written questionnaires pertaining to 241 patients. The number of patients per responding physician ranged from 1 to 38. Four of the 22 participating physicians were radiation oncologists; the rest were urologists. All radiation oncologists and all but four urologists were board certified in their respective disciplines. Urologists and radiation oncologists provided treatment data on 78.9% and 21.1% of patients, respectively. 143 (45) 127 (47) 120 (47) 115 (47) 112 (47) 139 (45) Employed at least part time, n (%)
157 (49) 138 (51) 131 (51) 128 (52) 113 (47) 151 (49) Reported at least two comorbidities, n (%)
177 (55) 143 (53) 140 (55) 129 (52) 132 (55) 171 (55) Household income <$40 000, n (%)
129 (40) 109 (40) 99 (39) 93 (38) 105 (44) 127 (41) Table 2 shows the agreement among different sources of reporting. With respect to reported prostatectomy, the highest level of agreement (kappa = 0.87) was observed when comparing caregivers' reports with patients' reports at 6 months after diagnosis, whereas the lowest level of agreement (kappa = 0.70) was found when patients' reports at 12 months of follow-up were compared with the physician questionnaire responses (Table 2A) . The corresponding kappa estimates ranged from 0.49 (caregivers' reports versus doctors' reports) to 0.75 (patient interviews at 6 and 12 months) for EBRT, from 0.72 (patients' report at 12 months versus physicians' questionnaires) to 0.90 (caregivers' reports and 6-month patients' reports) for brachytherapy, and from 0.35 (patients' reports at 6 months and doctors' reports at 12 months) to 0.76 (caregivers' reports and 6-month patients' reports) for hormonal treatment (Table 2B ). The analyses of the four-way agreement for all four reporting sources yielded the kappa values of 0.78 (95% CI 0.72-0.84) for prostatectomy, 0.58 (95% CI 0.52-0.64) for EBRT, 0.79 (95% CI 0.73-0.85) for brachytherapy, and 0.52 (95% CI 0.46-0.58) for hormonal treatment.
When each subjective reporting source was compared with the medical record abstracts ('gold standard'), 6-month patient interviews showed 96% sensitivity and 93% specificity for prostatectomy, 89% sensitivity and 79% specificity for EBRT, 94% sensitivity and 77% specificity for brachytherapy, and 60% sensitivity and 83% specificity for hormonal treatment ( Table 3) . The sensitivities and specificities of the 12-month patient interviews were within 63% of those observed for the 6-month patient interviews. The caregiver interviews had the sensitivities and specificities of 95% and 91%, 74% and 87%, 96% and 75%, and 58% and 88% for prostatectomy, EBRT, brachytherapy, and hormonal treatment, respectively. With respect to the range of results across all treatments and all reporting sources, doctors' reports appeared to have both the highest and the lowest specificity (97% for prostatectomy and 71% for brachytherapy) and the lowest sensitivity (40% for hormonal treatment) ( Table 3 ). The highest sensitivity (96% for prostatectomy) was found in the 6-month patients' reports. Table 4 shows that patients ‡65 years of age were more likely than their younger counterparts to misreport (primarily overreport) EBRT at 6 months after diagnosis (OR = 2.40; 95% CI 1.08-5.30) with the similar, but not statistically significant, association observed at 12 months of follow-up (OR = 2.07; 95% CI 0.88-4.87). When African-American patients were compared with Caucasians, there was a statistically significant association with misreporting (primarily due to underreporting) of EBRT during the 12-month interview (OR = 4.75; 95% CI 1.93-11.68), but not during the 6-month interview. Analyses of over-and underreported treatment did not demonstrate any consistent patterns.
As shown in Table 5 , the caregivers of African-American patients tended to incorrectly report EBRT (OR = 3.38; 95% CI 1.57-7.27), while analyses for all other patient characteristics demonstrated no significant departures from the null. With respect to the caregiver characteristics, wives and partners were significantly less likely to misreport prostatectomy compared with other types of caregivers with an OR of 0.07 (95% CI 0.01-0.44). A similar analysis evaluating factors associated with disagreement between medical record abstracts and physician questionnaires (Table  6) showed that physician questionnaires were more likely to misreport brachytherapy for married patients. Among physician-related variables, being in practice for <20 years was associated with misreporting of EBRT. As was the case with patient interviews, separate analyses of over-and underreporting showed no consistent patterns. To our knowledge, the current study represents the first known population-based analysis of agreement across multiple different sources of data on prostate cancer treatment. The agreement among different subjective reporting methods was generally in the good-to-excellent range for prostatectomy and brachytherapy and the fair-to-good range for EBRT and hormonal treatment. Similarly, using medical record abstracts as the gold standard, the interview-and questionnaire-based data collection methods were more accurate for prostatectomy and brachytherapy than for EBRT and hormonal therapy. We were unable to identify a particular patient, caregiver, or physician profile that would predispose to higher or lower level of reporting accuracy. Our literature search identified two previous studies that examined the agreement of patients' self-reported prostate cancer treatment with medical record abstraction results. In a 2001 publication, Clegg et al. used data from the Prostate Cancer Outcomes Study (PCOS) that was conducted to investigate the patterns of cancer care and the effects of initial treatments on health-related quality-of-life outcomes in a large population-based cohort of newly diagnosed prostate cancer patients [13, 14] . As in our study, the accuracy of self-reported prostatectomy and EBRT was high with the sensitivities and specificities in the 89%-98% range, whereas the corresponding results for hormonal treatment were lower particularly for hormonal pills with sensitivity of 69% [8] .
In a more recent study, Oberst et al. (2009) [15] examined agreement between medical record abstracts and self-reported treatment in a sample that included 291 prostate cancer patients recruited among cases reported to the Metropolitan Detroit Cancer Surveillance System (MDCSS). The selfreported treatment was ascertained during telephone interviews at 6 months after the prostate cancer diagnosis. The results for prostatectomy demonstrated that self-reports had a sensitivity of 92% and a specificity of 82%. For EBRT, the sensitivity and specificity were both 95% and for hormonal treatment, the study reported sensitivity of 74% and specificity of 92%.
While addressing the same research question, the studies by Clegg et al. [8] and Oberst et al. [15] are different from ours in several aspects. First, ours is the only one of the three studies that was conducted in a largely rural area. Secondly, the proportion of African-American patients (40%) in our study was higher than the corresponding proportions in the PCOS (10%) and MDCSS (25%) cohorts. Thirdly, unlike the PCOS and MDCSS studies, treatment options evaluated in our analyses included brachytherapy, in addition to EBRT, original articles Annals of Oncology prostatectomy, and hormonal treatment. Fourthly, patient and caregiver interviews in our study were conducted in person at the participants' homes, which provided an opportunity for the participants to ask questions and may have reduced the number of missing data. Finally, to our knowledge, ours is the only study that examined the validity and reliability of reported treatment from four different sources-a 6-month and a 12-month patient interview, a caregiver interview, and a written physician questionnaire. Although the above-mentioned methodological features should be considered as strengths, our study has also a number of disadvantages particularly when compared with the Clegg et al. (2001) report. The most important limitation of our cohort is its relatively small sample size, and for this reason, our study power and precision of estimates are much lower than those of PCOS, a multicenter project that included multiple sites. Further, unlike PCOS, hormonal treatment in our study did not distinguish between injections and pills, whereas the number of patients that underwent orchiectomy was too small to allow separate analyses.
Additional limitations of our study include lack of more detailed information on patients' insurance status and other caregiver-and provider-related characteristics. The composition of our study population did not allow inclusion of racial/ethnic groups other than Caucasians and African-Americans. From the data analysis point of view, a limited sample size precluded us from dividing potentially important variables such as participants' age, income, and comorbidities into more than two categories, and it is possible that some associations were missed. For example, it would be important to know if treatment misclassification is more or less common in persons with higher and lower levels of income (e.g. <$20 000 versus >$100 000 annually) or with higher or lower educational attainment (e.g. <8 years of school versus graduate education). The reasons for the low level of agreement for hormonal treatment require further exploration. Hormonal therapy is 
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somewhat different from other treatments because it is commonly administered along with surgery or radiation. When the data on hormonal treatment agreement were limited to patients that received a single treatment type (as opposed to a combination of two or more treatments), the accuracy of reporting was generally higher than in the overall study group. The sensitivities and specificities of hormonal treatment reporting increased from 83% to 100% and from 83% to 92% for the 6-month patient interviews, from 96% to 100% and from 75% to 94% for caregiver interviews, from 58% to 89% and from 85% to 90% for the 12-month patient interviews, and from 40% to 70% and from 83% to 85% for the doctor questionnaires. These comparisons indicate that the accuracy of reporting may be affected by the number of treatments received.
In recent years, much attention has been directed toward active surveillance as a viable alternative for prostate cancer management [16, 17] . Active surveillance is defined as a strategy that involves no immediate treatment; however, this option requires that patients undergo close monitoring of prostatespecific antigen kinetics and serial biopsies [18] . Although our 6-and 12-month interviews did not specifically ask about active surveillance, our data indicate that in this study population, this approach was used very rarely, if at all. Doctor's questionnaires identified active surveillance as a method used in six cases; however, all six of those patients reported receiving some kind of treatment.
A proper evaluation of agreement among various sources with respect to reported active surveillance would require a much higher frequency of interviews to be able to determine at which point a specific patient chose to forego expectant management in favor of a more aggressive treatment. It is also likely that active surveillance is yet to gain recognition in rural areas such as SWGA.
Although we assumed that medical record abstraction represents the 'gold standard' of data collection, it is possible original articles Annals of Oncology that medical record abstracts were also incomplete and/or inaccurate. Although the abstractors used in this study were highly trained and made an effort to obtain the data from multiple sources including private physician's offices, some of the medical records, particularly those related to hormonal therapy, may have been missed. As many of the patients in our study were over the age of 65, it would be important to explore Medicare records as an alternative source of treatment data because Medicare billing information would provide additional data from hard-to-obtain sources such as stand-alone medical offices and clinics.
It is important to point out that the cost of data abstraction may or may not be higher than the cost of interviews. For example, in this study, which relied on computer-assisted in-person interviews, the cost of data abstraction was lower than the cost of interviews. On the other hand, the interviews provided information about patients' preferences and quality of life that typically cannot be found in medical records.
We conclude that interviews and questionnaires provide useful although not necessarily more cost-effective alternatives to medical record abstraction for single procedure-based therapeutic options such as prostatectomy and brachytherapy, but they are less helpful for outpatient treatments such as EBRT and androgen deprivation therapy. Based on our data, compared with other report-based methods of data collection, patient or caregiver interviews at 6 months after diagnosis appear to provide the most accurate information regarding all prostate cancer treatment modalities. 
